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ABSTRACT 
 
Anti-atherosclerotic effect of 3-hydroxybenzaldehyde 
 
SooJung Im 
 
Department of Medical Science 
The Graduate School, Yonsei University 
 
(Directed by Professor Eun Jig Lee) 
 
Atherosclerosis is a complex vascular disease caused by thickening arterial wall, 
infilteration of leukocytes, abnormal proliferation and migration of vascular smooth 
muscle cells (VSMCs) and the formation of multiple atheromatous plaques within arteries.  
3-Hydroxybenzaldehyde (3-HBA) is one of the three isomers of hydroxybenzaldehyde 
and water-soluble phenolic aldehyde synthesized chemically, but its therapeutic function 
is unknown. In this study, the inhibitory role of 3-HBA on platelet derivative growth 
factor-induced migration and proliferation in VSMCs was studied. In addition, 3-HBA 
diminished signal-transduction involved in the inhibition of platelet derivative growth 
factor-induced migration and proliferation. Moreover, 3-HBA attenuated platelet 
aggregation in both in-vivo and ex-vivo conditions and prevented tail vein thrombosis 
induced by 𝜅-carrageenan injection. In these experiments, 3-HBA reduced blood 
aggregating velocity and length of thrombus in the tail of rats. These findings suggest a 
potential therapeutic role of 3-HBA in the treatment of atherosclerosis. 
Key word: atherosclerosis, 3-Hydroxybenzaldehyde, VSMC, PDGF, migration, 
proliferation, antithrombotic 
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I. INTRODUCTION 
 
Atherosclerosis is a complex disease that arterial walls become thickened and hardened 
by increased intima size. The accumulation of leukocytes and residues form atheroma and 
intensify the pathological disorder. Also repetitive vascular smooth muscle cells (VSMCs) 
migration and proliferation aggravate sclerosis.1-3  
Atherogenesis and intima hyperplasia cause various cardiovascular disorders, 
including heart failure, myocardial infarction and cerebral infarction.1,2,4 When the inner 
layers of arteries are injured, various cell types including endothelial cells, secrete 
cytokines and growth factors. These multiple factors such as platelet-derived growth 
factor (PDGF) induce VSMCs to change from quiescent state to synthetic state.1,5 PDGF 
is significant regulating factor of cell cycle of VSMCs, and also encourage the 
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movement.2 Thus PDGF stimulation increases the factors involved in proliferation of 
VSMCs and it activates matrix metralloproteinases (MMPs) to break down extracellular 
matrix to move.3,6 It is also known as an activator of protein kinase B (AKT) through the 
activation of Ras and phosphatidylinositol 3-Kinase (PI3K)7-9 As well as intima 
hyperplasia, atherothrombosis is fibrous wastes from inner arterial layer coagulate 
together and form platelet thrombi lead to vascular occlusion.2,6,10 Patients are prescribed 
an anticoagulants or antiplatelet drugs because of high relapsing possibility of this 
disease.11 
Protocatechuic aldehyde (PCA; 3,4-dihydroxybenzaldehyde) is a chemical compound 
that is found from various natural components such as Danshen which has been known as 
natural medicine for atherosclerosis.2,12 PCA is known as an inhibitor of proliferation and 
migration by PDGF in VSMCs and an anticoagulant. Unlike the limelight received PCA, 
3-hydroxybenzaldehyde is not reported for its therapeutic effectiveness and it also has 
structure that is lacking one hydroxyl group from PCA. In this study, we discovered that 
3-hydroxybenzaldehyde inhibits proliferation and migration of VSMCs causing intimal 
hyperplasia as well as platelet aggregation in in-vivo condition.  
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II. MATERIALS AND METHODS 
 
1. Production of 3-hydroxybenzaldehyde 
3-hydroxybenzaldehyde (3-HBA) was purchased from SIGMA-Aldrich (St. Louis, 
MO, USA). The powder was dissolved in 60 ˚C.-warmed distilled water for 2 hours with 
a rotary evaporator. Next, the solution was filtered by 0.2 μm pore cellulose acetate 
syringe filter (Satorious, Goettingen, Germany) diluted to final experimental 
concentrations. The solution was warmed to 60 ˚C every time to use. 
 
2. Primary cell isolation and culture  
Rat vascular smooth muscle cells (VSMCs) were isolated from the thoracic aorta of 6 
weeks SD male rats (Orient-Charles River Technology, Gyeonggido, Korea) and stored 
in liquid nitrogen after suspended in freezing medium (feral bovine serum with 10% 
DMSO). All experiment, VSMCs were utilized between passage 4 to 6. Cells were grown 
in Dulbecco's High Glucose Modified Eagles Medium (Hyclone, Logan, UT, USA) with 
10% of fetal bovine serum. For synchronization, cells were starved by same media without 
serum for 24 hours. After synchronization, cells were treated with 3-HBA for 24 hours 
prior to stimulation with platelet-derived growth factor (PDGF)-BB (R&D Systems, 
Minneapolls, MN, USA) for 24 or 48 hours up to the experiments.2,12,15  
 
3. Cell viability and proliferation assay 
After seeded 5 x 103 cells per well of 96 cell culture plate, cells are stabilization in 
200μl DMEM with 10% serum for a day and synchronize in 100μl DMEM without serum 
for a day. As treatment of 3-HBA (0, 25, 50, 100 μM), cells are exposed to media with 
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PDGF (25 ng/ml) for 24, 48 or 144 hours depending on the groups. The cells were 
subjected to the 10μl of Cell Titer 96®  AQ ueous Non-Radioactive MTS Cell 
Proliferation Assay (Promega, Madison, WI, USA) for 4 hours and the absorbance is read 
at a wavelength of 490 nm. The percentage of cell growth was evaluated by setting as 
100% the growth of control cells treated only media.2 
Proliferation was also determined by bromodeoxyuridine (BrdU) incorporation assay 
(Cell Proliferation ELISA; Roche, Basel, Switzerland). Cells were seeded as same as MTS 
assay, BrdU incorporation analysis was performed according to the recommended 
instructions. The absorbance was measured at 450 nm.2,12 
 
4. Propidium iodide staining for cell cycle analysis  
Propidium Iodide was purchased from SIGMA-Aldrich and prepared 500 ㎍/ml in 
PBS containing 10% FBS. Cells were collected by tripsinazation and resuspended in 0.3 
ml PBS containing 10%  FBS. Cells were fixed with pre-cold pure ethanol for over 2 
hours at – 20 ˚C, after twice of wash, stained in PI staining solution at room temperature 
for 30 minutes. Cell cycle analysis was evaluated with a flow cytometer (FACS Calibur, 
BD Biosciences, San Jose, CA, USA) and analyzed by flow-jo program.2 
 
5. Reverse transcription and quantitative real-time PCR (RT-PCR)  
Total RNA was extracted from cell lysates with Isol RNA lysis reagent (5 prime, 
Hilden, Germany) and cDNA was prepared using ReverTra Ace -α- ® (Toyobo, Osaka, 
Japan). All steps were was performed according to the recommended instructions. 
Oligonucleotide primers were synthesized from Bioneer (Seoul, Korea) and steps were 
followed by 30 cycles consisting denaturizing at 95˚C for 30 sec, annealing at 56˚C for 
6 
30 sec, and polymerizing at 72 ˚C for 5 min, followed by additional polymerizing at 72˚C 
for 5 min. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a loading 
control. PCR products were observed in 2% agarose gel electrophoresis. Amplified 
products were electrophoresed on 2% agarose gel with SafeView from NBS biologicals 
(Cambridgeshire, UK) and observed by ultraviolet trasnilluminator. 8,9 
 
6. Immunoblotting  
Cell lysates were prepared with RIPA buffer (Biosesang, Kyeonggido, Korea) 
containing phenymethylsulfonyl fluoride (1 mM), sodium fluoride (50 mM), sodium 
orthovanadate (0.2 mM), β-glycerophosphate (1 Mm) and protease inhibitor cocktail. 
Each chemical was purchased from Sigma-Aldrich except protease inhibitor cocktail 
(04693159001, Roche, Basel, Switzerland). Membranes were then immunoblotted with 
primary antibodies for phosphor-Akt (Cell Signaling, Beverly, MA, USA), Akt (Cell 
Signaling) and MMP-2 (Santa Cruz biotechnology, Santa Cruz, CA, USA). Every primary 
antibody was diluted 1:1000 in tris-buffered saline containing 0.05% tween 20 and with 
5% bovine serum albumin. 8,9 Peroxidase-conjugated anti-rabbit or anti-mouse antibodies 
were used as secondary antibodies (Thermo Fisher Scientific, Rockford, IL, USA). β-actin 
was used as a loading control.2,12 
 
7. Cell migration assay  
Upon VSMC reaching 80% of confluence in 6 well plate, the cell layer was scratched 
with a sterile plastic 1000 μl tip. Cell migration was photographed using a Nikon 
microscope system (Nikon Instruments, Inc., Melville, NY, USA). The area of wound 
healing was measured using Image J program (NIH). 
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8. Blood aggregation  
This study was performed with the approval of Institutional Animal Care and Use 
Committee of Yonsei University Health System based on the Laboratory Animal Manual 
and the “Guide for the care and use of laboratory animals” edited by the National Research 
Council of the National Academies (permit number 2012-0022-2). All animal studies 
were performed in facilities approved by the Association for Assessment and 
Accreditation of Laboratory Animal Care. All animal models were anesthetized with an 
intraperitoneal injection of Rumpun-Zoletile mixture once every procedure. 
The sample blood for ex-vivo was taken from two 6-week male Sprague Dawley rats 
(Orient-Charles River Technology, Gyunggido, Korea) and collected with heparin (1.0%, 
JW Pharmaceutical, Seoul, Korea) to prevent precoagulation and stored on ice. Also 
sample blood for in-vivo test was taken after the animals were pretreated 3-HBA and 
aspirin (100 mg/kg/d, n=6 in each groups) for 1 weeks via i.p. injection. The group of 
control was injected normal saline (JW Pharmaceutical, Seoul, Korea). Platelet 
aggregation was evaluated with an impedance aggregometer (Chrono-log model 700, 
Chronsolog Corporation, Havertown, PA, USA) and induced by ADP (20 μM, Sigma–
Aldrich Co.)2,12 
 
9. SD rat models for tail vein thrombosis  
Tail thrombosis was induced in 6-week male SD rats to evaluate the effect of 3-HBA 
on thrombosis formation. Rats were grouped into three (n=6), and in a group were injected 
3-HBA (100 mg/kg) once a day for a week intraperitoneally. The other groups were 
injected with the same volume of normal saline (JW Pharmaceutical, Seoul, Korea) as a 
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vehicle. All experimental animals were injected κ-carrageenan (1 mg/kg) via tail vein 
injection intravenously. After injection, the locations of 13 cm from tail tips were ligated 
for 10 minutes and untied. In a group which injected with vehicle were injected heparin 
(200 IU, JW Pharmaceutical, Seoul, Korea) intraperitoneally after 10 minutes from κ-
carrageenan injection.12,16 
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III. RESULTS 
 
1. VSMC mortality after 3-hydroxybenzaldehyde treatment 
The cytotoxicity of 3-HBA (Figure 1) was measured through cell viability using MTS 
assay in a dose-dependent manner. More than 90% of cells were viable after treatment 
with 12.5 – 400 μM of 3-HBA and the survival rate was over 50% at all concentration. 
(Figure 2)  
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Figure 1. Chemical structure of 3-HBA 
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Figure 2. The effect of 3-HBA on viability of rat VSMCs. VSMCs were starved for 24 h 
and treated with indicated concentration of 3-HBA for 48 hours. To investigate the effect 
of 3-HBA on the cell of rat VSMCs, an MTS assay was performed. Each value represents 
the absorbance at 490nm in cells compared to that in vehicle-treated cells which is 
arvitrarily denoted as 100%.  
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2. The inhibitory effect of 3-HBA on proliferation of rat VSMCs 
MTS assays were performed to confirm that 3-HBA suppresses VSMC proliferation 
induced by PDGF stimulation. Cell proliferation was inhibited by 3-HBA in a dose-
dependent manner for up to 144 hours of treatment (Figure 3A). BrdU incorporation assay 
was used to determine the rate of DNA synthesis. BrdU incorporation was greater on 
PDGF treated cells, while the result was reduced significantly on 3-HBA pretreated cells 
(Figure 3B). Also PDGF induces phosphorylation of AKT that is known as a modulator 
of various gene regulator protein activation was also inhibited 3-HBA treatment (Figure 
3C). 
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Figure 3. The inhibitory effect of 3-HBA on PDGF-induced proliferation of rat VSMCs. 
(A, B, C) VSMCs were starved serum for 24 hours and were pretreated 0, 25, 50, 100μM 
3-HBA for 24 hours. (A) Cells were stimulated with 10 ng/ml PDGF for 48 and 144 
hours. Media was changed every 48 hours. Cell proliferation was measured with MTS-
based assay, observed at 490 nm. (B) Cells were stimulated with 25 ng/ml PDGF for 48 
hours and labeled by BrdU. (C) Cells were stimulated with 10 ng/ml PDGF for 24 hours. 
Western blots are demonstrating the effects of PDGF and 3-HBA phosphorylated AKT 
(pAKT) from whole cell lysate. β-actin used as a loading control. Each results are 
expressed as the mean ± SEM (standard error of the mean). * represents statistical 
significant differences as compare to the group treated with PDGF alone (p < 0.05).  
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3. The inhibitory effect of 3-HBA on cell cycle of rat VSMCs. 
In VSMCs cell cycle, 3-HBA treatment decreased the number of cells at S and G2/M 
phase by PI staining (Figure 4A). In particularly, the results were observed that mRNA 
expression levels of CD1 and Rb1, which regulate cell cycle, were inhibited after 3-HBA 
treatment compared to in group treated with PDGF alone (Figure 4B). mRNA expression 
was measured by reverse transcription and quantitative real-time PCR (RT-PCR). Primers  
for ccnd1 and rb1 gene describe in Table 1. To conclude, 3-HBA arrests S and G2/M 
phase of cell cycle through Rb1 and CD1 on VSMCs.  
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Table 1. the sequences of primers 
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Figure 4. The inhibitory effect of 3-HBA on cell cycle of rat VSMCs. (A, B) VSMCs 
were starved in medium lacking serum for 24 hours, and then pretreated at indicated 
concentration of 3-HBA for 24 hours. VSMCs were then stimulated with PDGF (25 ng/ml) 
for 24 hours. (A) Cell cycle distribution was measured with PI staining. 3-HBA treatment 
decreased the number of cells at S and G2/M phase. (B) Gene expressed level was 
analyzed by reverse transcription and quantitative RT-PCR. mRNA expression levels of 
CD1 and Rb1 gene were inhibited after 3-HBA treatment. Each result is expressed as the 
mean ± SEM. * and ** indicate p<0.05 and p<0.005 compared to control group, 
respectively.  
 
19 
4. The inhibitory effect of 3-HBA on PDGF-induced migration of rat VSMCs.  
As assessment on migration of VSMCs is important criteria to evaluate the effect of 3-
HBA for treatment of atherosclerosis we have performed wound-healing experiments. In 
a dose dependent manner of 3-HBA inhibited the migration of VSMCs (Figure 5A). In 
accordance with the image, the graph showed that 3-HBA decreased the number of 
migrated cells. Moreover, the expression of MMP-2, an important protein marker for the 
migration of cell, also decreased significantly in 3-HBA treated group (Figure 5B). 
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Figure 5. The effect of 3-HBA on migration of rat VSMCs. (A, B) VSMCs were serum 
starved for 24 hours, and then pretreated with 3-HBA (0, 50, 100 μM) for 24 hours. 
VSMCs were stimulated with PDGF (A) 25 ng/ml and (B) 10ng/ml for 24 hours. (A) 
Before stimulation, wells were scratched, cells were stained by hematoxylin and scored 
by Image J program. VSMCs were inhibited from migrating in a dose dependent manner 
of 3-HBA. (B) Protein expression of MMP-2 was determined by western blot analysis. 
The expression of MMP-2 decreased significantly in 3-HBA treated group. β-actin was 
used as a loading control. Each result is expressed as the mean ± SEM. * indicates P<0.05 
compared to the PDGF treated group. 
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5. The anti-ADP-induced blood aggregation effect of 3-HBA on SD rats 
To evaluate inhibitory effect of 3-HBA on the rat platelet aggregation, ex-vivo and in-vivo 
experiments were performed. For the ex-vivo experiment, the sample blood was collected 
from SD rat whole blood and mixed with 3-HBA before aggregation assay. 3-HBA 
decreased the aggregation velocity dose-dependently in ADP (20 μM)-induced platelet 
aggregation (Figure 6A). For the in-vivo experiment, 3-HBA was introduced to rats for 1 
week. In-vivo result shows that 3-HBA has potential capability as an anti-platelet like 
aspirin (Figure 6B). 
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Figure 6. The blood thinning and restoration effect of 3-HBA on SD rat. (A, B) The 
sample blood was taken from 7-week-male SD rats. Platelet aggregation after 3-HBA 
treatment (A) ex-vivo condition and (B) in-vivo condition. (A, B) The platelet aggregation 
was induced by ADP. 3-HBA decreased the aggregation velocity dose-dependently in 
platelet aggregation. (A) 3-HBA and aspirin administered at a dose of 100 mg/kg/ for 1 
week by i. p. injection (𝑛=6 in each group). the aggregation velocity decreased 3-HBA 
treated as much as aspirin in platelet aggregation. (B) Results are expressed as the mean 
± SEM. * indicates statistical differences versus control group, respectively (p<0.05).  
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6.  The restoration effect of 3-HBA on κ-Carrageenan-induced tail vein thrombosis SD 
rat models 
To evaluate anti-thrombosis effect of 3-HBA, Bekemeier’s modified tail vein thrombosis 
model was performed. Three different SD rat groups were injected with substances for 
one week and utilized for this experiment, which are 3-HBA (100 mg/kg, n=6), positive 
control (heparin 200 IU, n=6), and sham-operated (normal saline, n=6). For positive group, 
normal saline was given like sham-operated groups, but heparin was injected to rats once 
along with 1mg/kg κ-carrageenan injection. Representative picture shows average 
thrombotic region of each group after 72 hours of Bekemeier’s model performed. Black 
line indicates the position of tail 13 cm from tail tip. At this position, tail was tied when 
tail vein thrombosis model was induced .The graph represents the length of thrombotic 
region throughout the different time interval (Figure 7). The length of thrombotic region 
were decreased the 3-HBA treated group as much as the heparin injected group. 
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Figure 7. The effect of 3-HBA on tail vein thrombosis SD rat models. 3-HBA (100 
mg/kg/d) administered for 1 week via i. p. injection and heparin (200 IU) was 
administered once via i.p. injection. The pictures represent gross changes in the tail vein 
72 hours after 𝜅-carrageenan injection. The black bar on the picture indicates the position 
13 cm from the tail tip. The dot graph represents change of gross length. Results are 
expressed as the mean ± SEM. * and ** indicate p<0.05 and p<0.005 compared to control 
group, respectively.  
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IV. DISCUSSIONS 
 
3-Hydroxybenzaldehyde (3-HBA) is one of the three isomers of hydroxybenzaldehyde 
and a chemically synthesized water-soluble phenolic aldehyde17. Like salicylalehyde (2-
hydroxybenzalhyde) that is another isomer of hydroxybenzaldehyde, 3-HBA used as a 
chelating reagent17, however, other function of 3-HBA has remained unknown. On the 
other hand, protocatechuic aldehyde (3, 4-dihydroxybenzaldehyde; PCA) with a similar 
structure is known the efficacy in cardiovascular diseases through various studies2,12,18-21. 
Especially, PCA is capable to prevent the proliferation and migration of VSMCs and has 
capacity of as an anticoagulant2.  
In the present study, we demonstrated that 1) 3-HBA prevents arteries from thickening 
by suppressing PDGF-induced VSMC proliferation and migration and 2) prevents 
thrombus formation. VSMCs show over 90% of viability even after 48 hours treatment in 
various dose of 3-HBA (Figure 2). Within this time range, 3-HBA showed its therapeutic 
effectiveness.  
Vascular migration and proliferation are considered as key steps in the progression of 
atherosclerosis1. From the MTS experiments, we found that both 3-HBA-pretreated 
groups for short and long term showed suppressing effect when cells were induced with 
PDGF (Figure 3A). Also, the upregulation of phosphorylation of AKT is a key modulator 
of cell proliferation1. In the present study, both the phosphorylated AKT and newly 
synthesized DNA labeled by BrdU were reduced after 3-HBA was treated (Figure 3B, C).  
In addition, VSMCs cell cycle inhibition is one of the therapeutic strategies for 
treatment of atherosclerosis22. Cell cycle progression is dependent on the expression and 
activation of cyclin-dependent kinase (CDK) with their regulatory coenzymes, the 
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cyclins23. In addition to interaction between CDK and cyclin complex, the E2F family of 
transcription factors with retinoblastoma protein controls expression of genes in quiescent 
condition24. In the present study, 3-HBA blocked cells from entering synthetic (S), gap 
(G2), and mitotic (M) phase. We believe that 3-HBA suppressed the expressions of cyclin 
D1 and Rb1 and regulated cells to enter quiescent (G0) phase. (Figure 4A, B). 
Also, MMP-2, so called gelatinase A, leads VSMCs migrate and neointimal thickening. 
We investigated that 3-HBA shows suppressing effect of VSMC migration by wound-
healing experiments and MMP-2 expression. 
Not only in VSMC migration and proliferation, but 3-HBA showed anti-platelet effect 
in experimental animals. Thrombotic occlusion is the major cause of heart attack or stroke. 
For patients at risk of ischemic stroke, antithrombotics, such as heparin and aspirin, are 
used therapeutically. It is known that when heparin injected to the patients, it acts by 
binding to antithrombin III. In contrast, aspirin inhibits platelet aggregation by blocking 
thromboxane A2 synthesis16,26. When 3-HBA introduced directly into whole blood, 
velocity of the platelet aggregation induced by ADP was decreased depending on the 3-
HBA concentration. Also, the velocity of aggregation whole blood collected from animals 
after 3-HBA injection for a week had similar results to that of aspirin treated animals. 
Moreover, when tail thrombus induced by 𝜅-carrageenan, the obstructed region of the tail 
was dissolved over time after 3-HBA administration for a week (Figure 7). Further 
researches are needed to verify the underlying mechanism of 3-HBA in attenuation of 
platelet aggregation.  
In conclusion, 3-HBA attenuated PDGF-induced VSMC proliferation and migration 
those are critical in pathophysiology of atherosclerosis by downregulating of the AKT 
phosphorylation and MMP-2 expression. Moreover, we observed that after administering 
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3-HBA, platelet aggregation was inhibited. These results provide that 3-HBA is a 
potential candidate for the development of new therapeutic drug to prevent and treat 
atherosclerosis.  
 
 
30 
V. CONCLUSION 
 
These results support that 3-hydroxybenzaldehyde affects in two different directions 
in atherosclerosis. 3-hydroxybenzaldehyde acts as an inhibitor of both proliferation and 
migration of VSMCs that play an important role on pathophysiologic process of 
atherosclerosis. 3-hydroxybenzaldehyde is responsible for inhibiting the activity of 
various enzymes and signal transmissions induced by PDGF in VSMC.  
Furthermore, 3-HBA shows the ability to reduce ADP-induced platelet aggregation in 
a dose-dependent manner and comparable effect of same dose of aspirin, well known as 
an antiplatelet. In addition, 3-HBA has an excellent effect in restoring from κ-
Carrageenan-induced thrombosis. 
3-hydroxybenzaldehyde has a possibility as a therapeutic component on the 
atherosclerotic diseases. 
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국문요약 
 
죽상동맥경화에 대한 3-hydroxybenzaldehyde의 효과 
 
<지도교수 이 은 직> 
 
연세대학교 대학원 의과학과 
 
임 수 정 
 
본 연구는 기능이 알려지지 않았던 3-hydroxybenzaldehyde (3-HBA)가 
혈관평활근세포에서 혈소판유래성장인자에 의한 증식 및 이동에 있어 
저해제의 역할과 래트의 조건에 형성된 죽상동맥경화모델에서 항응고제의 
역할을 통하여 신약개발의 후보로서의 가능성을 검증하는 것이다.  
3-HBA를 랫드의 혈관평활근세포에 전처리하였을 경우 혈소판유래성장인자가 
유도되어도 세포의 성장주기 및 분열, 이동이 억제되었다. 이에 관련된 
분자생물학적 변화양상은 Western blot및 PCR을 통하여 확인하였다. 또한 
직접 실험동물로부터 획득한 전혈에 3-HBA 를 도입하거나, 7 일간 직접 
동물에 3-HBA 를 투약하여 전혈을 채취한 경우 모두 ADP 로 혈전응고를 
유도하였을 때 혈전 형성 속도를 감소시키는 효과를 보였다. 뿐만 아니라 
7일간 3-HBA를 투약한 실험동물의 꼬리에 혈전을 형성하였을 경우, 형성된 
혈전이 완화됨을 확인하였다. 
결론적으로 본 연구를 통하여 물질 3-HBA가 죽상동맥경화의 병리학적 양상인 
혈관평활근세포의 증식 및 이동을 억제함과 혈전형성의 억제를 통하여 
죽상동맥경화의 예방약물로의 가능성이 있다는 것을 시사한다. 
핵심되는 말 : 죽상동맥경화, 혈전용해제, 혈관평활근세포, 3-HBA. , 3-
Hydroxybenzaldehyde 
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